Two merge to form Jazz Pharmaceuticals

by emma 21. September 2011 15:30

Pharma Field industry news

Jazz Pharmaceuticals and Irish-based Azur Pharma Limited have combined to create a new speciality company.

The combined company – which will continue as Jazz Pharmaceuticals plc– will be incorporated in Ireland and has several products currently marketed in the US.

Seamus Mulligan, Chairman and CEO, Azur Pharma, says the merger creates a company that has “greater operational and financial resources” to enable its strategy of acquiring and developing speciality products.

The company markets ten products in the US within the central nervous system (CNS) and women’s health areas. Including Xyrem, Luvox CR, Prialt, FazaClo and Elestrin, revenues are now expected to reach more than $475 million in the first 12 months following the completion of the deal.

The combined company would also have a number of pipeline of lower-risk development programmes, including line extensions for the clozapine franchise and various other branded women’s health products.

"This significant transaction represents a compelling strategic fit, given our companies' closely aligned missions of identifying and developing products that address unmet patient needs and can be efficiently marketed through a specialty commercial infrastructure," said Bruce Cozadd, who will become the Chairman and CEO of Jazz Pharmaceuticals plc.

Sanofi in R&D deal for acne vaccine

by emma 21. September 2011 15:04

Pharma Field industry news

Sanofi Pasteur has signed a research and development agreement with the University of California, San Diego, for its experimental acne vaccine and treatment.

The R&D pact includes a two-year collaboration with Chun-Ming Huang and team at UC San Diego School of Medicine.

The team’s immunological approach to acne prevention and treatment targets the neutralisation of Propionibacterium inflammation.

Elias Zerhouni, President of Global Research and Development at Sanofi, said that the vaccine and treatment could address an unmet medical need.

“This investigational vaccine and treatment may lead to a better solution for the many who suffer from this skin disease,” said Mr Zerhouni.

According to the vaccine division of Sanofi, the annual market for acne therapeutics is in excess of $3 billion.

Pfizer invests in Ireland

by emma 21. September 2011 13:07

Pf industry news

Pfizer is to invest $200 million at its Grange Castle biotechnology manufacturing site in Clondalkin, County Dublin.

The new investment will see Pfizer introduce two new processing suites to expand its current production and product testing capabilities.

Frank D’Amelio, Chief Financial Officer, Pfizer, says “Ireland is a prime location for this major investment” after a “long history in pharmaceutical excellence”.

The biotechnology manufacturing facility is already one of the largest in the world and produces two of Pfizer’s main products, Prevnar and Enbrel.

More than 1,100 staff are currently employed at the site. Irish Prime Minister Enda Kenny says that the new investment highlights “the tremendous contribution to Ireland’s life sciences industry since it (Pfizer) first established here in 1969 and this investment is a further demonstration of the company’s continuous commitment”.

In total, Pfizer has 4,300 staff employed across the country in eight separate locations in Cork, Dublin, Kildare and Limerick. Its latest investment means the company’s outlay now exceeds $7 billion in the country.

Sanofi continues OPV support

by emma 21. September 2011 12:47

Pf industry news

Sanofi Pasteur is donating a vaccine strain used for polio eradication to the World Health Organization (WHO) to produce oral polio vaccines (OPV).

The vaccines division of Sanofi is providing the original viral seed which is used to produce large volumes of OPV against the type 3 virus.

Olivier Charmeil, President and CEO of Sanofi Pasteur, says the donation is a “logical next step” in the division’s “unconditional support to OPV producers”.

Since its inception in 1988 by WHO, Rotary International, the US Centers for Disease Control and Prevention (CDC) and UNICEF, the Global Polio Eradication Initiative reduced the number of polio cases across the globe by 99%.

Sanofi Pasteur has supported the Initiative for the last three decades and recently responded to a request from UNICEF by committing to provide 400 million doses of OPV for use in developing countries. The donation saw the amount of doses provided by Sanofi Pasteur exceed five billion doses of OPV to UNICEF.

“Sanofi Pasteur is a leading contributor to the fight against polio and committed supporter of the Global Polio Eradication Initiative," added Sanofi Pasteur’s President.

WHO will now be in full control of the storage of the vaccine strain and its distribution to vaccine producers across the globe.

Getting the message across

by emma 28. July 2011 16:54

xavier louyot

Talking business isn’t restricted to exclusively speaking English. Xavier Louyot (pictured), Dolce Hotels and Resorts, explains how multilingual content can create global opportunities for your business.

Generating content for global markets and communicating to a multilingual audience is a challenge that comes part and parcel of a global position or organisation, especially given the pressure to standardise and comply with internal and international standards.

A common risk is to see the meaning in your messages either lost or altered because of these language differences. Culture, translation, writing, and design always interweave in curious ways when presenting to a multilingual audience; so keeping it simple is often the key to avoid misinterpretation and to keep communication lines clear and concise.

By putting some simple techniques into practice you can ensure that you get your message across effectively and accurately to your associates and clients, not just in their language, but in ways that show that you value and respect their culture.

Keeping it simple

Start by keeping sentences short and, where possible, use bullet points. This is good practice in any presentation; but is even more important if you are communicating to audiences in a language that is not their mother tongue. Bullet points allow a speaker to identify clear key points and keep audiences focused on the most important or relevant elements of the presentation.

In the same way that sentences should be short, the vocabulary and grammar chosen should be as easy and simple as possible for audiences to understand. Sticking to plain words and sentence structures will ensure the audience is focussed on the presentation and not pre-occupied by a word they cannot translate or understand.

Of course, there will always be times when it’s hard to avoid certain words or expressions that do not translate. Perhaps you need to use a colloquial term or a reference to the local dialect, either way, in this instance it is useful and completely appropriate to give audiences an explanation or definition of the word or expression. This enables you to put it within the intended context and avoids any confusion or the message being diluted.

A common interest

It’s often hard with multilingual audiences to find a shared interest but it’s this common ground that helps communities come together and can really make or break a conference. Including references or giving examples that resonate across cultures is an effective way to develop a rapport with your audience and, at the same time, bring delegates together. Building this sense of camaraderie amongst audiences can often lead to more productive breakout sessions and networking around a conference or event.

Finally, it’s useful to remember that it’s best to use formal language when addressing a multilingual audience. Informal vocabulary is very specific to each culture and is not always learnt when a language is being taught at school or university. Sticking to formal language ensures you don’t alienate your audience or worse still, offend them.

The above are just a small amount of tips and hints to put into practice when communicating to a multilingual audience; but most of all, the best tool you have is your smile. A person who smiles exudes friendliness, openness and approachability.

Even if audiences don’t understand everything you have said, say it with a smile and they will feel comfortable enough to approach you with a question. For something that is universally understood and costs nothing to give, the value of a smile cannot be underestimated when it comes to breaking down language barriers and engaging international audiences.

Xavier Louyot is Global Director, Marketing and PR for Dolce Hotels and Resorts.

TextBox

Tag cloud

Calendar

<<  May 2013  >>
MoTuWeThFrSaSu
293012345
6789101112
13141516171819
20212223242526
272829303112
3456789

View posts in large calendar